Travere Strikes $112.5M Civorebrutinib Deal, Analyst Sees 49% Upside
TVTX•Travere Therapeutics will pay $112.5 million upfront, up to $1.03 billion in milestone payments and royalties for global rights to civorebrutinib, an early-stage oral kidney-disease therapy. H.C. Wainwright upped its price target to $67 from $57 with a Buy rating, implying about 49% upside after positive early data.
1. Licensing Deal Details
Travere acquired exclusive rights to civorebrutinib outside China and select Asian markets by paying $112.5 million upfront, with up to $1.03 billion in potential milestone payments and royalties ranging from high single digits to low double digits.
2. Clinical Data Highlights
Early data from a small patient study showed rapid reductions in pathogenic antibodies and urinary protein, sustained kidney function stability for up to one year and minimal side effects, supporting potential best-in-class status.
3. Analyst Upgrade
H.C. Wainwright raised its price target by 18% to $67, reiterated its Buy rating and cited the early data and drug profile as reasons for an implied 49% upside.
4. Development and Next Steps
Travere will advance civorebrutinib into trials for primary membranous nephropathy, focal segmental glomerulosclerosis and minimal change disease, with potential expansion into related rare-kidney disorders pending regulatory clearances.
